Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00085358
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:13.701657+00:00
Published At
2019-07-22T00:00:00+00:00
Record Updated At
2019-07-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Brenner Tumor", "Fallopian Tube Cancer", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mixed Epithelial Carcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Undifferentiated Adenocarcinoma", "Primary Peritoneal Cavity Cancer", "Stage II Ovarian Epithelial Cancer", "Stage III Ovarian Epithelial Cancer", "Stage IV Ovarian Epithelial Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-07-22"
protocolSection.identificationModule.nctId
"NCT00085358"
protocolSection.identificationModule.officialTitle
"A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinosarcoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mixed Epithelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Undifferentiated Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Cavity Cancer (protocolSection.conditionsModule.conditions)
  • Stage II Ovarian Epithelial Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Ovarian Epithelial Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Epithelial Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.